» Articles » PMID: 17898680

The Natural History of Untreated Chlamydia Trachomatis Infection in the Interval Between Screening and Returning for Treatment

Overview
Journal Sex Transm Dis
Date 2007 Sep 28
PMID 17898680
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies of the natural history of genital chlamydial infections in humans are sparse and have had study design limitations. An improved understanding of chlamydial natural history may influence recommendations for elements of control efforts such as chlamydia screening frequency or time parameters for partner notification.

Methods: Addressing limitations of prior studies in part, we are prospectively studying chlamydial natural history in sexually transmitted diseases clinic patients in the interval between screening and returning for treatment of positive chlamydial tests. Results of repeat chlamydial testing and clinical outcomes and their associated predictors are being evaluated.

Results: In the initial 129 subjects, 89% were female, 88% were black, median age was 21 years, and the median interval between screening and treatment was 13 days. Based on nucleic acid amplification testing at treatment, spontaneous resolution of chlamydia occurred in 18%. Resolution was somewhat more common in subjects with longer intervals between screening and treatment. Persisting infections more often progressed to develop clinical signs at the time of treatment (e.g., urethritis or cervicitis). Two women and one man developed chlamydial complications between screening and treatment.

Conclusions: Our findings demonstrate that although spontaneous resolution of chlamydia is common, many persons with persisting chlamydia progress to develop signs of infection and some develop complications.

Citing Articles

Association of burden with the vaginal microbiota, bacterial vaginosis, and metronidazole treatment.

Ardizzone C, Taylor C, Toh E, Lillis R, Elnaggar J, Lammons J Front Cell Infect Microbiol. 2023; 13:1289449.

PMID: 38149008 PMC: 10750252. DOI: 10.3389/fcimb.2023.1289449.


Using infection prevalence, seroprevalence and case report data to estimate chlamydial infection incidence.

Clay P, Pollock E, Copen C, Anyalechi E, Danavall D, Hong J Sex Transm Infect. 2023; 99(8):513-519.

PMID: 37648446 PMC: 11323310. DOI: 10.1136/sextrans-2023-055808.


Bacterial Vaginosis and Spontaneous Clearance of Chlamydia trachomatis in the Longitudinal Study of Vaginal Flora.

Brown S, Tuddenham S, Shardell M, Klebanoff M, Ghanem K, Brotman R J Infect Dis. 2023; 228(6):783-791.

PMID: 37158693 PMC: 10503950. DOI: 10.1093/infdis/jiad142.


Estimated costs and quality-adjusted life-years lost due to N. gonorrhoeae infections acquired in 2015 in the United States: A modelling study of overall burden and disparities by age, race/ethnicity, and other factors.

Li Y, Ronn M, Tuite A, Chesson H, Gift T, Trikalinos T Lancet Reg Health Am. 2023; 16:100364.

PMID: 36777156 PMC: 9904145. DOI: 10.1016/j.lana.2022.100364.


Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial.

Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E Clin Infect Dis. 2022; 76(5):881-889.

PMID: 36250382 PMC: 7614294. DOI: 10.1093/cid/ciac824.